Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Beta Bionics (BBNX) Cost of Revenue (2024 - 2026)

Beta Bionics' Cost of Revenue history spans 3 years, with the latest figure at $20.7 million for Q1 2026.

  • On a quarterly basis, Cost of Revenue rose 139.21% to $20.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $61.7 million, a 71.12% increase, with the full-year FY2025 number at $44.7 million, up 52.94% from a year prior.
  • Cost of Revenue hit $20.7 million in Q1 2026 for Beta Bionics, up from $13.2 million in the prior quarter.
  • Over the last five years, Cost of Revenue for BBNX hit a ceiling of $20.7 million in Q1 2026 and a floor of $5.7 million in Q1 2024.
  • Historically, Cost of Revenue has averaged $11.5 million across 3 years, with a median of $9.6 million in 2024.
  • Biggest five-year swings in Cost of Revenue: rose 25.81% in 2025 and later surged 139.21% in 2026.
  • Tracing BBNX's Cost of Revenue over 3 years: stood at $8.8 million in 2024, then soared by 50.58% to $13.2 million in 2025, then surged by 57.36% to $20.7 million in 2026.
  • Business Quant data shows Cost of Revenue for BBNX at $20.7 million in Q1 2026, $13.2 million in Q4 2025, and $12.1 million in Q3 2025.